✦ LIBER ✦

Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin

✍ Scribed by V. K. RUSTGI; S. ESPOSITO; F. M. HAMZEH; M. L. SHIFFMAN

Book ID: 108605216
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 87 KB
Volume: 27
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2007.03587.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon alfa-2b and weight-based o

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

✍ Ira M. Jacobson; Robert S. Brown Jr; Bradley Freilich; Nezam Afdhal; Paul Y. Kwo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

Clifford A. Brass, 15 and the WIN-R Study Group This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with

Peginterferon alfa-2b plus ribavirin tre

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C

✍ Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullm 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Peginterferon plus ribavirin is standard therapy for adults with chronic hepatitis C. As no data are available for children, the aim of the study was to evaluate the efficacy and tolerability of peginterferon alfa-2b in combination with ribavirin in chronically infected children. Genotypes, alanine

Early virologic response after peginterf

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

✍ A. M. Di Bisceglie; R. H. Ghalib; F. M. Hamzeh; V. K. Rustgi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Prediction of response to peginterferon-

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

✍ Yoshimasa Hashimoto; Hidenori Ochi; Hiromi Abe; Yasufumi Hayashida; Masataka Tsu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

## Abstract Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and v

Pharmacodynamics of peginterferon alfa-2

Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

✍ R. BRUNO; P. SACCHI; C. SCAGNOLARI; F. TORRIANI; L. MAIOCCHI; S. PATRUNO; F. BEL 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB

Impact of weight-based ribavirin with pe

Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1

✍ Ira M. Jacobson; Robert S. Brown Jr; Jonathan McCone; Martin Black; Clive Albert 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 1 views

Brass, 14 for the WIN-R Study Group WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b